Recombinant Hyaluronidase (Under development)

Recombinant Hyaluronidase (Under development)
Product Description

Antibodies are regards as anticancer "magic bullet". Monoclonal Antibody (MAb therapeutics) Market  will grow USD300 billion in 2025. For these therapeutics, a lot of companies are under development of SC formulation with recombinant Hyaluronidase (using human rHuPH20), and BMI Korea's recombinant hyaluronidase can be alternative for existing products. 

BMI Korea

  • KR
  • 2015
    On CPHI since
  • 3
    Certificates
  • 100 - 249
    Employees
Company types
Manufacturer/Innovator

BMI Korea

  • KR
  • 2015
    On CPHI since
  • 3
    Certificates
  • 100 - 249
    Employees
Company types
Manufacturer/Innovator

More Products from BMI Korea (8)